Microbiome and Rectal Cancer

Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

This study will help to further elucidate the association of bacteria with rectal cancer, while also characterizing the genes associated with that risk. Furthermore it will attempt to better understand which patients may have an optimal response to neoadjuvant chemoradiation allowing for possible predictive metagenomics evaluation, investigators may be able to augment treatments as well as provide recommendations for the success and cost effectiveness of cancer care.

Inclusion Criteria:

• Age ≥ 18 years old
• Locally Advanced Rectal Adenocarcinoma (T3)
• Standard 5FU based chemoradiation
• Total Neoadjuvant Therapy per OPRA protocol guidelines

Exclusion Criteria:

• Age < 18 years
• Stage I or Stage IV rectal adenocarcinoma
• Rectal cancer other than adenocarcinoma
• Genetically associated cancer (HNPCC, FAP etc.) or highly suspicious for genetically associated cancer
• Prior history of rectal adenocarcinoma (i.e. recurrent colorectal adenocarcinoma)